retatrutide trial sign up FDA Approval Status: July 2026 Update retatrutide trials sign up retatrutide

Evidence Snapshot The STEP trials demonstrated significant weight reduction with semaglutide, with gastrointestinal side effects most prominent during dose escalation. Long-term micronutrient outcomes were not primary endpoints

Using a mouse model, we demonstrate that exogenous serotonin administration in mice lowers plasma glucose, potentially via increases in both plasma insulin and GLP-1 levels

Uninsured patients represent one of the fastest-growing populations seeking weight loss medication, driven by rising obesity rates and limited employer-sponsored coverage options

PMID: 29 CsordasG.RenkenC.VarnaiP.WalterL.WeaverD.ButtleK

Their impact is usually comparable